HUANG, SHANSHAN
 Distribuzione geografica
Continente #
NA - Nord America 39
EU - Europa 28
AS - Asia 9
AF - Africa 5
Totale 81
Nazione #
US - Stati Uniti d'America 39
SE - Svezia 9
IN - India 8
DE - Germania 6
GB - Regno Unito 6
TG - Togo 5
IE - Irlanda 3
IT - Italia 2
CZ - Repubblica Ceca 1
FR - Francia 1
SG - Singapore 1
Totale 81
Città #
Chandler 6
Southend 6
Lomé 5
Princeton 4
Redmond 4
Dublin 3
Ashburn 2
Fairfield 2
Medford 2
Pune 2
Ann Arbor 1
Brno 1
Des Moines 1
Houston 1
Hyderabad 1
Munich 1
Olalla 1
San Diego 1
Santa Clara 1
Singapore 1
Wilmington 1
Totale 47
Nome #
Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035)) 53
Erratum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035)) 31
Totale 84
Categoria #
all - tutte 470
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 470


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 0 5
2021/202236 0 1 2 8 5 2 0 1 2 3 7 5
2022/202333 2 4 3 2 3 4 3 4 7 1 0 0
2023/20247 0 2 1 0 0 2 0 0 0 0 0 2
2024/20253 1 2 0 0 0 0 0 0 0 0 0 0
Totale 84